Aplastic anaemia is a rare haematopoietic stem-cell disorder. The condition results in pancytopenia and hypocellular bone marrow. Most cases are acquired, however, there are unusual inherited forms.
On this page:
Pathology
Aplastic anaemia manifests as a marked reduction in the number of pluripotent haematopoietic stem cells. It is immune-mediated in most cases where autoreactive lymphocytes mediate the destruction of haematopoietic stem cells. Environmental exposures (e.g. drugs, viruses, and toxins) are thought to initiate the aberrant immune response in some patients, but most cases are classified as idiopathic.
Radiographic features
MRI
Signal characteristics follow differences in fatty versus haematopoietic marrow. Reported patterns include 3:
focal low-signal (both TI and T2) areas (likely representing islands of active haematopoietic cells) interspersed with high-SI areas in the marrow of the spine. Note this pattern is also seen in lymphoma, metastases and myeloma.
diffuse high-signal marrow without focal abnormalities in the pelvis and proximal femoral regions
MRI is also useful for assessment of response to treatment in aplastic anaemia as well as other haematopoietic disorders 4.
Treatment and prognosis
Similar to other autoimmune diseases, aplastic anaemia has a varied clinical course which ranges from some patients having mild symptoms that necessitate little or no therapy to others presenting with life-threatening pancytopenia. Acquired aplastic anaemia can be effectively treated by allogeneic bone-marrow transplantation, immunosuppression (generally anti-thymocyte globulin and ciclosporin), and high-dose cyclophosphamide.
Complications
development of paroxysmal nocturnal haemoglobinuria (PNH)
development of myelodysplastic syndrome
Unable to process the form. Check for errors and try again.